News & Updates
Filter by Specialty:

Testosterone therapy in women may lower risks of MACE, breast cancer
Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.
Testosterone therapy in women may lower risks of MACE, breast cancer
04 Jun 2024
Legume intake reduces colorectal cancer risk
Eating legumes may help avert the development of colorectal cancer, according to a study that has found an inverse association between legume consumption and colorectal cancer risk.
Legume intake reduces colorectal cancer risk
03 Jun 2024
Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.
Arginine depletion plus chemo ups survival in rare lung cancer
31 May 2024
Thyroid cancer patients with a history of breast cancer enjoy survival benefits
A history of breast cancer (BC) appears protective against mortality in patients with thyroid cancer (TC), suggests a study. This benefit is most pronounced with papillary TC (PTC) in patients who had TC first before BC (TC-1st patients), especially in those with a history of ER-positive BC.
Thyroid cancer patients with a history of breast cancer enjoy survival benefits
30 May 2024
MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133
Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.